Decentralised Clinical Trials (DCTs) can facilitate broader and more diverse patient participation. We look at the benefits and challenges of DCTs, and explore how far we’re likely to see them take over from conventional trials in the coming years.
Clinical trials have traditionally required participants to visit specific study sites for assessments and interventions, which can be inconvenient and costly, leading to challenges in terms of recruitment and often limited representation of certain demographics. According to US company Medrio, in 50 per cent of trials, potential participants are widely dispersed or have difficulty staying enrolled due to poor health, and 70 percent of patients live over two hours from a research sitNew technology has opened up a new type of trial. The availability of digital health technologies (DHTs) such as activity trackers, glucose monitors and other devices means that trial participants do not necessarily need to attend a traditional clinical trial site. In addition, mobile apps can be used by patients to log their own data (such as pain and depression) or take part in cognitive and other tests.
While these technologies enable healthcare organisations to capture information directly from individuals while they are going about their daily lives, DCTs can also utilise local healthcare facilities or home visits to reduce the need for participants to travel.
The advantages of DCTs are clear. They are more convenient for volunteers, reduce time and expenses, and can cast a far wider net for recruitment – not only in terms of location but also diversity. Being able to participate in a study from home makes it easier for people who are older, have disabilities or caregiving responsibilities, or simply do not live near to clinical research facilities.
On the other hand, DCTs and DHTs can present barriers of their own – particularly around technology. A recent article by the MD Group2 highlighted that DCTs can bring challenges in terms of finding new technology vendors, processing high volumes of patient data, and technological failure.
Implementing DCTs also requires training for clinical research staff and participants to ensure that technologies are used correctly. There are logistical challenges around transporting treatments safely, and storing electronic data securely.
As technology advances and people become more comfortable with DHTs and remote healthcare in their daily lives, DCTs will continue to grow, although hybrid models are likely to become the most common. One thing is certain: with patients being asked to take an ever-more active role in recording their data, educating potential volunteers about the trial process will be vital to ensure broad participation.
At Absolutely Health, we prioritise staying abreast of advancements in healthcare technology and their implications for clinical trial recruitment. By leveraging these developments, we aim to reach broader demographics compared to traditional in-person trials and enhance the education of potential volunteers regarding participation requirements. Our strategies are comprehensive, considering all aspects and potential opportunities within this evolving landscape.
